乙型肝炎患者血清HBV前C区A83变异株的检测

Detection of Serum HBV preC A83 Mutant in Hepatitis B Patients

目的:探讨乙型肝炎病毒(HBV)前C区A83点突变与临床关系。方法:采用聚合酶链反应(PCR)对64例乙型肝炎(乙肝)患者HBV前C区基因进行扩增,对PCR产物进行限制性片段长度多态性分析(RFLP),鉴定前C区第83位核苷酸点突变。结果:34例(53.13%)有A83点突变,其中12例(18.75%)为单独变异株感染,22例(34.38%)为变异株与野毒株混合感染。慢性乙型肝炎(CHB)和肝硬化(LC)组高于无症状HBV携带者(ASC)(P<0.05)。抗-HBe(+)组的检出率为70.0%,高于HBeAg(+)组的25.0%(P<0.01),并且随着HBVDNA含量的增高,其发生变异的可能性越大(P<0.05)。结论:前C区A83点突变的发生可能与机体长期的炎症活动、免疫压力的选择有关。

Objective: To discuss the relationship between HBV preC A83 point mutation and clinic. Methods: HBV preC gene was amplified by polymerase chain reaction (PCR) and the PCR production was analyzed by restriction fragment length polymorphism (RFLP) in 64 HBV patients. PreC point mutation of 83 nucleotide was identified. Results: Twelve (18.75%) single mutation infection and 22 (34.38%) mutation and wild mixed infection were found in 34 (53.13%) preC A83 mutations. The preC A83 mutation rates in chronic hepatitis B (CHB) group and liver cirrhosis (LC) group were higher than that in asymptomatic HBV carries (ASC) group (P < 0.05). The rate was higher in anti-HBe positive group (70.0%) than that in HBeAg positive group (25.0%) (P < 0.01). The possibility of mutation was higher along with the increase of HBV DNA quantity (P<0.05). Conclusion: The preC A83 mutation may be related to the long-term inflammation and immune pressure.